30 closest matches · ranked by relevance
Stem Cell Transplantation
Primary: Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade…
Non-ischemic Dilated Cardiomyopathy
Primary: Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs) — 1; 0; 0; 1 Participants
Liver Cirrhosis
Primary: Number of Participants With Serious Adverse Events Related to Injection — 0 Participants
Stem Cell Transplantation · Ventricular Dysfunction, Left
Primary: Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade…
Ischemic Cardiomyopathy
Primary: Safety of Autologous-bone-marrow Injections — 1; 1; 0; 1 participants
Coronary Artery Disease
Primary: Safety of Aldehyde Dehydrogenase Bright Stem Cells Versus the Control Group as Measured by Combined Early and Late Adverse Events — 10; 10; 0; 2 participants
Myocardial Infarction
Primary: Myocardial Blood Flow at Baseline and 3-month Follow-up — 0.62; -0.27; 0.44; 0 ml/min/g
Leukemia
Primary: Median Time to Engraftment of Neutrophils — 11; 11 days
Type 1 Diabetes · Type 2 Diabetes
Primary: Number of Participants Who Experienced Adverse Events — 1; 7 participants
Healthy
Primary: Change in Cytokine Gene Expression Profiles (84 Genes) in T Cells Following G-CSF Administration — 16 unique cytokine genes affected
Left Ventricular Dysfunction
Primary: Global Left Ventricular Function — 0.5; 3.6 percentage of ejection fraction — p=<0.05
Multiple Sclerosis
Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale
Sickle Cell Disease
Primary: Number of Participants With Sufficient Collection of Hemopoietic Stem Cells (HSCs) Without Serious Adverse Events — 14 Participants
Adult Stem Cell Proliferation
Primary: Percentage of CD133+ Cells — 0.50; 0.28; 0.54; 0.47 percent of total
Cardiomyopathy Due to Anthracyclines
Primary: Proportion of Major Adverse Cardiac Events (MACE) — 3; 6 events
Liver Cirrhosis
Primary: Patient Survival — 5; 6; 4; 10 participants — p=0.4340
Glioma · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities
Cleft Lip and Palate
Primary: Amount of New Bone Mass Formed — 89 percentage of bone formation
Left Ventricular Dysfunction
Primary: Global Left Ventricular Function — 3.5; 4.4; 2.8; 1.7 percentage of ejection fraction — p=0.959
Liver Disease
Primary: Number of Patients Who Tolerated the Maximum Dose — 5 Participants
Leukemia · Lymphoma
Primary: Number of Participants With Absolute Neutrophil Count Engraftment — 21 participant
Hypoplastic Left Heart Syndrome · Single Ventricle · Heart Failure
Primary: Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells — 0; 0 participants
Periapical Periodontitis
Primary: Number of Participats Showing Efficacy (Functionality) — 18; 18 Participants
Coronary Artery Disease
Primary: Myocardial Defect Perfusion — 15.76; 15.38; 2.08; 3.85 Percentage of Myocardial Perfusion
Breast Reconstruction · Contour Irregularities · Volume Insufficiency
Primary: Volume Maintenance — 51.6; 78.9 percentage of graft volume persistency — p=0.310
Chronic Ischemic Heart Disease · Left Ventricular Dysfunction · Angina
Primary: Change in Maximal Oxygen Consumption (VO2max) — -0.6; 0.4 mL/kg/min — p=0.169
Acute Myelogenous Leukemia
Primary: Percentage of Participants With Relapse Free Survival at 1 Year — 56 percentage of participants
Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA) · Severe Aplastic Anemia (SAA)
Primary: Number of Participants Who Engrafted by Day 42 — 30 Participants
Xerostomia
Primary: Number of Participants With Adverse Events as a Measure of Safety — 0; 0 participants
Dilated Cardiomyopathy
Primary: Heart Failure Mortality — 8; 19 participants — p=0.01